International scientific cooperation to advance image-guided prostate cancer care

February 07, 2012

Reston, VA (Feb. 7, 2012) - To improve early diagnosis and treatment of prostate cancer, ACR, AdMeTech Foundation and ESUR have formed a joint effort to expedite development of standards for the Magnetic Resonance Prostate Imaging Reporting and Data System (MR PI-RADS) modeled after a successful effort in breast cancer care. The goal is to expedite the transfer of high-quality MRI from laboratories to patients to address the major need in prostate cancer care -- reducing unnecessary biopsies and treatment. Over-diagnosis and over-treatment associated with current prostate cancer screening (PSA testing) has been highlighted by the United States Preventive Services Task Force, American Cancer Society and other groups. MR PI-RADS is expected to be completed and ready for distribution in early 2013.

"MR PI-RADS will build on the ACR's experience with the Breast Imaging Reporting and Data System (BI-RADS®) that has led to improvements in breast cancer screening and treatment worldwide. This new system will continue the good stewardship of vital healthcare resources clearly demonstrated by radiologists in the past," said Jeffrey Weinreb, MD, ACR representative and co-chair of the MR PI-RADS Steering Committee.

MR PI-RADS will be based on prostate MRI guidelines developed by ESUR and the work by the AdMeTech Foundation's International Prostate MRI Working Group.

"This tool will set the standards for prostate MRI reporting and help more efficiently combat prostate cancer by reducing unnecessary biopsies and focusing resources on those patients who truly need further treatment," said Jelle Barentsz, MD, ESUR representative and co-chair of the MR PI-RADS ACR's Steering Committee.

"Prostate cancer -- the most common major cancer in the United States and the second most lethal malignancy in men -- represents a major public health problem. Advanced imaging technologies and their BI-RADS standardization enabled minimally-invasive, precisely-targeted diagnosis and treatment of breast cancer for women. Similarly, MR PI-RADS will transform prostate cancer care for men," said Faina Shtern, MD, AdMeTech Foundation's representative and a member of the ACR'S Steering Committee.
-end-
To arrange an interview with a spokesperson please contact Shawn Farley at 703.648.8936 or PR@acr.org.

About American College of Radiology: The ACR is a national professional organization serving more than 34,000 radiologists, radiation oncologists, interventional radiologists, nuclear medicine physicians and medical physicists with programs focusing on the practice of radiology and the delivery of comprehensive health care services.

About AdMeTech Foundation: A Boston-based non-profit organization providing leadership for ground-breaking programs in research, education and awareness to advance diagnostic tools for improved early detection and treatment of prostate cancer. AdMeTech Foundation gratefully acknowledges the support from the Telemedicine & Advanced Technologies Research Center (TATRC). AdMeTech Foundation's International Prostate MRI Working Group's research and development were made possible by a grant awarded and managed by the U.S. Army Medical Research & Materiel Command (USAMRMC) and TATRC, at Fort Detrick, MD under Contract Number: W81XWH-09-0552 (www.admetech.org).

About ESUR: The European Society of Uro-genital Radiology (ESUR) was founded in 1990, to promote high quality science and clinical practice of uro-genital radiology. Members of the ESUR are the World leading radiologists in uro-genital radiology. This society was especially successful with establishment of guidelines such as on the safe use of contrast media and on female genital imaging, and recently on standardization of prostate MRI.

American College of Radiology

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.